We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The announcement “likely signals that China is gearing up its enforcement efforts and looking into those industries that are most prone to corruption risk, particularly the pharmaceutical industry,” the attorneys said. Read More
An administrative law judge tossed out the Federal Trade Commission’s complaint challenging an agreement between Impax Laboratories and Endo Pharmaceuticals that the FTC claims illegally kept a generic version of the opioid pain medication Opana ER off the market. Read More
FDA officials indicated that the shortest median time to meaningful pain relief in the pivotal trial was 92 minutes — longer than the hour in which patients generally expect pain relief to take effect. Read More
Merck is appealing a decision that reinstated a class-action lawsuit alleging that the company failed to warn thousands of women taking Fosamax that they were at risk for thigh fractures. Read More
Spending on U.S. cancer medicines nearly doubled over the last five years—and may well double again in the next five years, a new report from IQVIA claims. Read More
The Trump administration is urging the Supreme Court to take up a case testing whether the FDA’s refusal to approve a warning label on drugs preempts state laws that may require such labels. Read More
Pfizer agreed to pay $23.85 million and enter into a five-year corporate integrity agreement to settle U.S. government claims that the company engaged in illegal kickbacks to Medicare patients that were masked by an independent charity. Read More